Genomic features of exceptional response in vemurafenib ± cobimetinib–treated patients with BRAF(V600)-mutated metastatic melanoma

PURPOSE: Previous investigations identified transcriptional signatures associated with innate resistance to anti–programmed cell death protein 1 therapy in melanoma. This analysis aimed to increase understanding of the role of baseline genetic features in the variability of response to BRAF and MEK...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Cancer Res
Auteurs principaux: Yan, Yibing, Wongchenko, Matthew J., Robert, Caroline, Larkin, James, Ascierto, Paolo A., Dréno, Brigitte, Maio, Michele, Garbe, Claus, Chapman, Paul B., Sosman, Jeffrey A., Shi, Zhen, Koeppen, Hartmut, Hsu, Jessie J., Chang, Ilsung, Caro, Ivor, Rooney, Isabelle, McArthur, Grant A., Ribas, Antoni
Format: Artigo
Langue:Inglês
Publié: 2019
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8083896/
https://ncbi.nlm.nih.gov/pubmed/30824584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-0720
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires